Cingulate Inc. Share Price

Cingulate Inc. Share Price

NASDAQ: CING | Micro Cap
$5.29
-$0.23 (-4.17%) Last updated on 29 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Cingulate Inc. Stock Performance

Open
$5.33
Prev. Close
$5.52
Circuit Range
N/A
Day Range
$4.96 - $5.33
Year Range
$3.19 - $11.78
Volume
5,604
Average Traded
$5.10

Cingulate Inc. Share Price Today

As of 29 October 2026, Cingulate Inc.'s share price is $5.29. The stock opened at $5.33, compared to its previous close of $5.52. During today's trading session, Cingulate Inc.'s share price traded between $4.96 and $5.33, with an average price of $5.14. Over the past 52 weeks, the stock has recorded a high of $11.78 and a low of $3.19. In terms of performance, Cingulate Inc.'s share price has risen by 3.42% over the last six months and is up 40.13% on a year-on-year basis.

Cingulate Inc. Share Price Chart

Line chart of the Cingulate Inc. price trend over the selected period. The price fell overall, ranging from 5.27 to 5.27, ending at 5.27.
$4.96$5.33
L
Show Current Price
H

Cingulate Inc. Stock Fundamentals & Key Indicators

Market Cap
$26.74M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.98
Revenue (TTM)
$0.00
Return On Equity (TTM)
-122.71%
Profit Margin
N/A
Debt to Equity
0.22
Quarterly Earnings Growth YoY
20.03%

Cingulate Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$7.34-$6.27-$9.31-$5.87
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A14.58%-48.48%36.95%

Cingulate Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$17.68-$23.53-$16.56-$22.45
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-33.09%29.62%-35.57%

About Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Cingulate Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$4.80
$5.29
+6.87%
Sep 2026
$5.16
$4.95
-8.16%
Aug 2026
$4.87
$5.39
+12.76%
Jul 2026
$5.63
$4.78
-12.29%
Jun 2026
$3.29
$5.45
+32.12%
May 2026
$5.16
$4.13
-19.35%
Apr 2026
$6.38
$5.12
-16.90%
Mar 2026
$6.01
$6.16
-1.83%
Feb 2026
$5.87
$6.27
+9.62%
Jan 2026
$4.31
$5.72
+32.71%
Dec 2025
$3.65
$4.31
+16.02%
Nov 2025
$3.69
$3.71
-1.59%

CING Share Price FAQs